NCT06054893View on ClinicalTrials.gov

A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old

PHASE1RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

February 21, 2030

Study Completion Date

February 21, 2030

Conditions
Friedreich Ataxia
Interventions
DRUG

Omaveloxolone

Administered as specified in the treatment arm

Trial Locations (1)

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT06054893 - A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old | Biotech Hunter | Biotech Hunter